Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
HMGA1
REST API REST API
Homo sapiens
HMGA1 is differentially expressed in 335 experiments: 136 organism parts: bone marrow, prostate, ... (134 more);, 240 disease states: normal, prostate carcinoma, ... (238 more);, 104 cell types 407 cell lines 46 compound treatments and 81 other conditions.
Synonyms HMGIY
Orthologs hmga1a (Danio rerio)   Hmga1-rs1 (Mus musculus)   HMGA1 (Bos taurus)   Hmga1 (Mus musculus)   hmga1b (Danio rerio)   RGD1564836 (Rattus norvegicus)   Hmga1 (Rattus norvegicus)   HMGA1_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term negative regulation of chromatin silencing, cytosol, DNA binding, negative regulation of transcription, DNA-dependent, protein binding, regulation of transcription, DNA-dependent, negative regulation of cell proliferation, transcription, DNA-dependent, DNA-(apurinic or apyrimidinic site) lyase activity, protein complex assembly, transcription factor binding, nucleus, ligand-dependent nuclear receptor transcription coactivator activity, transcription factor complex, DNA unwinding involved in replication, chromosome, chromatin, nucleoplasm, base-excision repair, enzyme binding, positive regulation of transcription, DNA-dependent, AT DNA binding, viral reproduction, retinoid X receptor binding, peroxisome proliferator activated receptor binding, response to virus, interspecies interaction between organisms, 5'-deoxyribose-5-phosphate lyase activity, nucleosome disassembly, retinoic acid receptor binding, sequence-specific DNA binding transcription factor activity, provirus integration, initiation of viral infection, positive regulation of cellular senescence, senescence-associated heterochromatin focus formation, senescence-associated heterochromatin focus, oncogene-induced senescence
InterPro Term AT_hook_DNA-bd_motif, HMGI/HMGY, AT_hook-like
UniProt Accession Q5T6U8, P17096
Gene-Disease Assocation DIABETES MELLITUS, NONINSULIN-DEPENDENT; NIDDM
Search EB-eye ENSG00000137309
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-MEXP-433, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, ... (45 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-3529, E-GEOD-19639
PC3
3
E-GEOD-5258, E-GEOD-14464, E-MEXP-2034
HL-60
2
E-GEOD-5258, E-GEOD-24147
MOLT4
2
E-MTAB-37, E-MTAB-62
BT474
1
2
E-MTAB-62, E-MTAB-37, E-MEXP-440
HCC2218
1
E-MTAB-37
401 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, E-GEOD-21909, ... (52 experiments)

Factor Value U/D Experiments
hematopoietic stem cell
2
E-MEXP-1403, E-MEXP-872
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
endothelial cell
2
E-GEOD-3920, E-GEOD-19240
monocyte
2
3
E-GEOD-5099, E-MEXP-583, E-GEOD-11755, E-GEOD-22373, E-GEOD-995 ... (5 experiments)
epithelial cell
1
2
E-GEOD-4483, E-GEOD-10797, E-MEXP-2034
activated natural killer cell (supplemented for IL2 for 24 hours)
1
E-TABM-702
98 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-1577, E-TABM-15, ... (67 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-GEOD-2514, E-MTAB-62, E-MEXP-231
Duchenne muscular dystrophy
2
E-GEOD-3307, E-GEOD-1004
Burkitt's lymphoma
2
E-MTAB-37, E-GEOD-96
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
acute quadriplegic myopathy
2
E-MTAB-62, E-GEOD-3307
cervical carcinoma
2
E-MTAB-62, E-MEXP-1331
234 more value(s).


Compound treatment

studied in E-GEOD-5741, E-GEOD-697, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (29 experiments)

Factor Value U/D Experiments
none
4
8
E-GEOD-5741, E-GEOD-5824, E-GEOD-412, E-GEOD-6907, E-GEOD-5099, ... (12 experiments)
ethanol
2
E-MEXP-2241, E-GEOD-3113
U0126
1
E-GEOD-697
epidermal growth factor
1
E-GEOD-6462
interferon-gamma + lipopolysaccharide
1
E-GEOD-7307
unknown
1
E-GEOD-7307
40 more value(s).


A rna yield

studied in E-TABM-325

Factor Value U/D Experiments
47.81
1
1
E-TABM-325


Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

Biosource provider
studied in E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21374, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-3325, E-TABM-147, E-GEOD-21138, E-GEOD-3013 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (7 experiments)

Genotype
studied in E-GEOD-2152, E-GEOD-1045, E-GEOD-17476, E-GEOD-22593, E-TABM-601, ... (15 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-TABM-127, E-GEOD-20540, E-GEOD-20504, ... (11 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-1926, E-MEXP-2069, E-MEXP-1648, ... (33 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

Organism
studied in E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phenotype
studied in E-GEOD-7819, E-GEOD-19703, E-GEOD-21750, E-GEOD-1460, E-GEOD-17636, ... (6 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797, E-GEOD-18791

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-13818, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-3494, E-TABM-43, E-GEOD-1561, E-GEOD-4922, E-TABM-147 ... (5 experiments)

Tumor size
studied in E-GEOD-6532

Processing time: 0.456 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM